Skip to main content
Caplight Logo









Gate Bioscience

Gate Bioscience

Private
Brisbane, CaliforniaHealthcare & Life Scienceshttps://gatebio.com

Last Round

Series B

Nov 13, 2025

Est. Valuation

$161M

Total Funding Raised

$135M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gate Bioscience operates in Healthcare & Life Sciences and is based in Brisbane, California. Its latest recorded funding round was a Series B round in November 2025.

Gate Bioscience is a biotechnology company that develops small molecule drugs known as Molecular Gates to selectively eliminate disease-causing extracellular proteins at their source within cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Gate Bioscience Comparables

Compare Gate Bioscience with similar companies based on industry and business-model similarity.

Gate Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Magnet Biomedicine
81%
Plexium
80%
Proxygen
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Gate Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 13, 2025
Series ANov 1, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Raman Talwar

Co-founder and CTO

Founding Team

Jordi Mata-Fink

Co-Founder and CEO

Founding Team

For institutional investors. Book with your work email.

Gate Bioscience Investors

Notable investors and investment history

Gate Bioscience investors
InvestorRounds
Andreessen HorowitzSeed, Series B, Series A
GVSeries A, Series B
ForbionSeries B
ARCH Venture PartnersSeries A, Series B
Versant VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 36% MoM, reaching 2.3K.

  • Jul 25, 2026

    Monthly visitors increased 36% MoM to 1.7K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • partners_withOct 6, 2026

    GateBioscience, Inc. partners with Lilly International to expand their multi-year collaboration and license agreement to discover, develop, and commercialize molecular gate therapeutics, adding one target and an option for a second in California on Oct 5th '26.

  • is_developingOct 5, 2026

    GateBioscience, Inc. is developing oral medicines that eliminate disease-causing proteins with Eli Lilly under an expanded partnership announced on Oct 6th '26, adding one target and an option to select a second.

Book a demo to see all news

For institutional investors. Book with your work email.

Gate Bioscience Filings

Explore SEC and related filing metadata, where available.

Gate Bioscience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Gate Bioscience's valuation, stock price, and market status.

Is Gate Bioscience a public or private company?

Gate Bioscience is a private company.

What is the current stock price of Gate Bioscience?

Gate Bioscience is a private company, so its shares have no public market price. Caplight tracks Gate Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Gate Bioscience worth (valuation)?

Gate Bioscience's valuation is estimated at $161.0M based on funding round data.

Can I buy Gate Bioscience stock?

Gate Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Gate Bioscience's last funding round?

Gate Bioscience's most recent funding round was Series B on November 13, 2025.

Who are the main investors in Gate Bioscience?

Key investors in Gate Bioscience include Andreessen Horowitz, Forbion, Versant Ventures.

Will Gate Bioscience IPO soon?

No public IPO plans have been announced for Gate Bioscience.

How can I track Gate Bioscience secondary market activity?

Caplight tracks bids, offers, and trades in Gate Bioscience's shares on secondary markets.

Firmographic Details

HeadquartersBrisbane, California
Employee Range38
Year Founded2021
Last FundingNov 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?